Versant Venture Management, LLC Long-Term Concentrated

Location: San Francisco, CA

CIK: 0001560009 · Show all filings

Period: Q4 2023 (← Previous) (Next →)

Filing Date: Feb 8, 2024

Total Value: $389M (100.0% shares, 0.0% debt)

Holdings (7)

— RayzeBio, Inc. 82.5%

Value $321M Shares 5,158,161 Est. Cost $22.20 Unrealized —

CRSP CRISPR Therapeutics AG 8.0%

Value $31.21M Shares 498,558 Est. Cost $40.26 Unrealized +36.7%

— Repare Therapeutics, Inc. 5.0%

Value $19.32M Shares 2,646,657 Est. Cost $10.58 Unrealized —

— Gritstone Bio, Inc. 1.9%

Value $7.265M Shares 3,561,150 Est. Cost $7767.86 Unrealized —

— Passage Bio, Inc. 1.3%

Value $5.009M Shares 4,959,769 Est. Cost $17.48 Unrealized —

— Adverum Biotechnologies, Inc. 1.0%

Value $3.815M Shares 5,068,233 Est. Cost $9646.10 Unrealized —

— Aligos Therapeutics, Inc. 0.4%

Value $1.541M Shares 2,320,381 Est. Cost $27.65 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
—	RayzeBio, Inc.	5,158,161	$321M	82.5%	$22.20	—	Common Stock	75525N107
CRSP	CRISPR Therapeutics AG	498,558	$31.21M	8.0%	$40.26	+36.7%	Common Shares	H17182108
—	Repare Therapeutics, Inc.	2,646,657	$19.32M	5.0%	$10.58	—	Common Stock	760273102
—	Gritstone Bio, Inc.	3,561,150	$7.265M	1.9%	$7767.86	—	Common Stock	39868T105
—	Passage Bio, Inc.	4,959,769	$5.009M	1.3%	$17.48	—	Common Stock	702712100
—	Adverum Biotechnologies, Inc.	5,068,233	$3.815M	1.0%	$9646.10	—	Common Stock	00773U108
—	Aligos Therapeutics, Inc.	2,320,381	$1.541M	0.4%	$27.65	—	Common Stock	01626L105